دورية أكاديمية
HOXA1 silencing inhibits cisplatin resistance of oral squamous cell carcinoma cells via IκB/NF-κB signaling pathway.
| العنوان: | HOXA1 silencing inhibits cisplatin resistance of oral squamous cell carcinoma cells via IκB/NF-κB signaling pathway. |
|---|---|
| المؤلفون: | Zhu R; School of Stomatology, Xuzhou Medical University., Mao Y; School of Stomatology, Xuzhou Medical University., Xu X; School of Stomatology, Xuzhou Medical University., Li Y; School of Stomatology, Xuzhou Medical University., Zheng J; School of Stomatology, Xuzhou Medical University.; Department of Oral and Maxillofacial Surgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu Province, China. |
| المصدر: | Anti-cancer drugs [Anticancer Drugs] 2024 Jul 01; Vol. 35 (6), pp. 492-500. Date of Electronic Publication: 2024 Mar 12. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Lippincott Williams & Wilkins Country of Publication: England NLM ID: 9100823 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1473-5741 (Electronic) Linking ISSN: 09594973 NLM ISO Abbreviation: Anticancer Drugs Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: London : Lippincott Williams & Wilkins Original Publication: Oxford, UK : Rapid Communications of Oxford, [1990- |
| مواضيع طبية MeSH: | Cisplatin*/pharmacology , Mouth Neoplasms*/drug therapy , Mouth Neoplasms*/pathology , Mouth Neoplasms*/genetics , Drug Resistance, Neoplasm* , Homeodomain Proteins*/genetics , Homeodomain Proteins*/metabolism , Signal Transduction*/drug effects , NF-kappa B*/metabolism, Humans ; Apoptosis/drug effects ; Carcinoma, Squamous Cell/drug therapy ; Carcinoma, Squamous Cell/genetics ; Carcinoma, Squamous Cell/pathology ; Carcinoma, Squamous Cell/metabolism ; Antineoplastic Agents/pharmacology ; Cell Line, Tumor ; Transcription Factors/genetics ; Transcription Factors/metabolism ; Squamous Cell Carcinoma of Head and Neck/drug therapy ; Squamous Cell Carcinoma of Head and Neck/genetics ; Squamous Cell Carcinoma of Head and Neck/pathology ; Squamous Cell Carcinoma of Head and Neck/metabolism ; NF-KappaB Inhibitor alpha/metabolism ; Cell Survival/drug effects ; Cell Proliferation/drug effects ; I-kappa B Proteins/metabolism |
| مستخلص: | The resistance of oral squamous cell carcinoma (OSCC) cells to cisplatin remains a tough nut to crack in OSCC therapy. Homeobox A1 (HOXA1) overexpression has been detected in head and neck squamous carcinoma (HNSC). Accordingly, this study aims to explore the potential role and mechanism of HOXA1 on cisplatin resistance in OSCC. The expression of HOXA1 in HNSC and its role in overall survival (OS) rate of OSCC patients were analyzed by bioinformatic analysis. Following transfection as needed, OSCC cells were induced by different concentrations of cisplatin, and the cell viability and apoptosis were evaluated by cell counting kit-8 and flow cytometry assays. The mRNA and protein expression levels of HOXA1 and the phosphorylation of IκBα and p65 were determined by real-time quantitative PCR and western blot. HOXA1 expression level was upregulated in HNSC tissues and OSCC cells. Overexpressed HOXA1 was correlated with a low OS rate of OSCC patients. Cisplatin exerted an anti-cancer effect on OSCC cells. HOXA1 silencing or cisplatin suppressed OSCC cell viability, boosted the apoptosis, and repressed the phosphorylation of IκBα and p65. Intriguingly, the combination of HOXA1 silencing and cisplatin generated a stronger anti-cancer effect on OSCC cells than their single use. HOXA1 silencing attenuates cisplatin resistance of OSCC cells via IκB/NF-κB signaling pathway, hinting that HOXA1 is a biomarker associated with OSCC and HOXA1 silencing can enhance the sensitivity of OSCC cells to cisplatin. (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.) |
| References: | Scully C, Bagan J. Oral squamous cell carcinoma: overview of current understanding of aetiopathogenesis and clinical implications. Oral Dis 2009; 15:388–399. Agnihotri NS, Astekar M. The role of novel prognostic markers PROX1 and FOXC2 in carcinogenesis of oral squamous cell carcinoma. J Exp Ther Oncol 2018; 12:171–184. Scully C. Oral squamous cell carcinoma; from an hypothesis about a virus, to concern about possible sexual transmission. Oral Oncol 2002; 38:227–234. Scully C, Sudbo J, Speight PM. Progress in determining the malignant potential of oral lesions. J Oral Pathol Med 2003; 32:251–256. Lorch JH, Goloubeva O, Haddad RI, Cullen K, Sarlis N, Tishler R, et al. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol 2011; 12:153–159. Abbas M, Alqahtani MS, Alshahrani MY, Alabdullh K. Aggressive and drug-resistant pancreatic cancer: challenges and novel treatment approaches. Discov Med 2022; 34:158–164. Meng X, Lou QY, Yang WY, Wang YR, Chen R, Wang L, et al. The role of non-coding RNAs in drug resistance of oral squamous cell carcinoma and therapeutic potential. Cancer Commun (Lond) 2021; 41:981–1006. Cheng Y, Li S, Gao L, Zhi K, Ren W. The molecular basis and therapeutic aspects of cisplatin resistance in oral squamous cell carcinoma. Front Oncol 2021; 11:761379. Wang XC, Ma Y, Meng PS, Han JL, Yu HY, Bi LJ. miR-433 inhibits oral squamous cell carcinoma (OSCC) cell growth and metastasis by targeting HDAC6. Oral Oncol 2015; 51:674–682. Cantó C, Gerhart-Hines Z, Feige JN, Lagouge M, Noriega L, Milne JC, et al. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature 2009; 458:1056–1060. Xiong P, Li YX, Tang YT, Chen HG. Proteomic analyses of Sirt1-mediated cisplatin resistance in OSCC cell line. Protein J 2011; 30:499–508. Ding J, Sun D, Xie P. Elevated microRNA-145 inhibits the development of oral squamous cell carcinoma through inactivating ERK/MAPK signaling pathway by down-regulating HOXA1. Biosci Rep 2019; 39:BSR20182214. Lee JC, Chung LC, Chen YJ, Feng TH, Chen WT, Juang HH. Upregulation of B-cell translocation gene 2 by epigallocatechin-3-gallate via p38 and ERK signaling blocks cell proliferation in human oral squamous cell carcinoma cells. Cancer Lett 2015; 360:310–318. Grier DG, Thompson A, Kwasniewska A, McGonigle GJ, Halliday HL, Lappin TR. The pathophysiology of HOX genes and their role in cancer. J Pathol 2005; 205:154–171. Hassan NMM, Hamada J-i, Murai T, Seino A, Takahashi Y, Tada M, et al. Aberrant expression of HOX genes in oral dysplasia and squamous cell carcinoma tissues. Oncol Res 2006; 16:217–224. Shah N, Sukumar S. The Hox genes and their roles in oncogenesis. Nat Rev Cancer 2010; 10:361–371. Zhang X, Emerald BS, Mukhina S, Mohankumar KM, Kraemer A, Yap AS, et al. HOXA1 is required for E-cadherin-dependent anchorage-independent survival of human mammary carcinoma cells. J Biol Chem 2006; 281:6471–6481. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25:402–408. Wardwell-Ozgo J, Dogruluk T, Gifford A, Zhang Y, Heffernan TP, van Doorn R, et al. HOXA1 drives melanoma tumor growth and metastasis and elicits an invasion gene expression signature that prognosticates clinical outcome. Oncogene 2014; 33:1017–1026. Bitu CC, Destro MF, Carrera M, da Silva SD, Graner E, Kowalski LP, et al. HOXA1 is overexpressed in oral squamous cell carcinomas and its expression is correlated with poor prognosis. BMC Cancer 2012; 12:146. Zhang X, Zhu T, Chen Y, Mertani HC, Lee KO, Lobie PE. Human growth hormone-regulated HOXA1 is a human mammary epithelial oncogene. J Biol Chem 2003; 278:7580–7590. Avinash Tejasvi ML, Maragathavalli G, Putcha UK, Ramakrishna M, Vijayaraghavan R, Anulekha Avinash CK. Impact of ERCC1 gene polymorphisms on response to cisplatin based therapy in oral squamous cell carcinoma (OSCC) patients. Indian J Pathol Microbiol 2020; 63:538–543. Hung C-C, Li F-A, Liang S-S, Wang L-F, Lin IL, Chiu C-C, et al. Direct binding of cisplatin to p22phox, an endoplasmic reticulum (ER) membrane protein, contributes to cisplatin resistance in oral squamous cell carcinoma (OSCC) cells. Molecules 2020; 25:3815. Li X, Guo S, Xiong X-K, Peng B-Y, Huang J-M, Chen M-F, et al. Combination of quercetin and cisplatin enhances apoptosis in OSCC cells by downregulating xIAP through the NF-kappa B pathway. J Cancer 2019; 10:4509–4521. Gu Y-x, Fan S-s, Wang C-k, Peng B, Zhang W-j, He Z-m. Effects of TCRP1 on mediating resistance to cisplatin in vivo in OSCC. Zhongguo Yaolixue Tongbao 2012; 28:1574–1578. Wei W, Piao S, Yao S, Bin Z, Wang J. miR-21 inhibitor sensitizes human OSCC cells to cisplatin. Mol Biol Rep 2012; 39:5481–5485. Hung CC, Chien CY, Chu PY, Wu YJ, Lin CS, Huang CJ, et al. Differential resistance to platinum-based drugs and 5-fluorouracil in p22phox-overexpressing oral squamous cell carcinoma: implications of alternative treatment strategies. Head Neck 2017; 39:1621–1630. Almeida LO, Abrahao AC, Rosselli-Murai LK, Giudice FS, Zagni C, Leopoldino AM, et al. NFκB mediates cisplatin resistance through histone modifications in head and neck squamous cell carcinoma (HNSCC). FEBS Open Bio 2014; 4:96–104. Gu Y, Fan S, Liu B, Zheng G, Yu Y, Ouyang Y, et al. TCRP1 promotes radioresistance of oral squamous cell carcinoma cells via Akt signal pathway. Mol Cell Biochem 2011; 357:107–113. Napetschnig J, Wu H. Molecular basis of NF-kappaB signaling. Annu Rev Biophys 2013; 42:443–468. Oeckinghaus A, Hayden MS, Ghosh S. Crosstalk in NF-kappaB signaling pathways. Nat Immunol 2011; 12:695–708. Hayden MS, Ghosh S. Signaling to NF-kappa B. Genes Dev 2004; 18:2195–2224. Babiuch K, Kusnierz-Cabala B, Kesek B, Okon K, Darczuk D, Chomyszyn-Gajewska M. Evaluation of proinflammatory, NF-kappaB dependent cytokines: IL-1alpha, IL-6, IL-8, and TNF-alpha in tissue specimens and saliva of patients with oral squamous cell carcinoma and oral potentially malignant disorders. J Clin Med 2020; 9:867. Johnson J, Shi Z, Liu Y, Stack MS. Inhibitors of NF-kappaB reverse cellular invasion and target gene upregulation in an experimental model of aggressive oral squamous cell carcinoma. Oral Oncol 2014; 50:468–477. |
| المشرفين على المادة: | Q20Q21Q62J (Cisplatin) 0 (Homeodomain Proteins) 0 (homeobox A1 protein) 0 (NF-kappa B) 0 (Antineoplastic Agents) 0 (Transcription Factors) 139874-52-5 (NF-KappaB Inhibitor alpha) 0 (I-kappa B Proteins) |
| تواريخ الأحداث: | Date Created: 20240313 Date Completed: 20240508 Latest Revision: 20240512 |
| رمز التحديث: | 20240513 |
| DOI: | 10.1097/CAD.0000000000001592 |
| PMID: | 38477942 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1473-5741 |
|---|---|
| DOI: | 10.1097/CAD.0000000000001592 |